Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jan 2026

Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis

Highlights • Tofacitinib improved ASAS response in ankylosing spondylitis patients.• It ameliorated disease activity, physical function, and quality of life.• 5 mg dose and 16-week treatment showed most favorable efficacy trends.• Safety similar to placebo except for higher risk of upper respiratory infection.

Le Shen, K. Han, Lei Bo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.